Haji Chalchal

<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Christos S. Karapetis, Shirin Khambata‐Ford, Derek J. Jonker et al. · New England Journal of Medicine · 2008 · 3.6K citations

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial

Paul E. Goss, James N. Ingle, Kathleen I. Pritchard et al. · Journal of Clinical Oncology · 2013 · 258 citations

Rituximab Therapy for Patients With Newly Diagnosed, Advanced-Stage, Follicular Grade I Non-Hodgkin's Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group

Thomas E. Witzig, Allen M. Vukov, Thomas M. Habermann et al. · Journal of Clinical Oncology · 2005 · 202 citations · Full text

Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer

Margot J. Burnell, Mark N. Levine, Judith‐Anne W. Chapman et al. · Journal of Clinical Oncology · 2009 · 152 citations · Full text

Surgical Oncology, Breast Oncology, Cancer Management +18